This randomized trial aimed at validating the efficacy and safety of low-dose decitabine, together with umbilical cord blood in PGF post allo-HSCT patients.
Diagnosed as PGF at day 28 post-HSCT or later. PGF was defined as two or three cytopenias, absolute neutrophil count ≤ 1.5 × 109/L, platelet count ≤ 30 × 109/L, hemoglobin ≤ 85g/L, lasting for more than 2 consecutive weeks;
Full donor chimerism;
Primary disease in remission;
No severe GVHD and relapse.
Allergic to decitabine or any components of frozen preservation of umbilical cord blood;
Active infections;
Uncontrolled GVHD;
Severe organ dysfunction;